Drug Trial Radar · NCT07746271
Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
4,120
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Dec 31, 2029
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- The George Washington University Biostatistics CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); University of Alabama at Birmingham; University of Utah; Brown University
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 14 years, up to 56 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase-III multi-center open-label randomized clinical trial of 4,120 individuals between 23 weeks, 0 days and 35 weeks, 6 days gestation with gestational hypertension or preeclampsia without severe features randomized to antihypertensive medication to a target blood pressure (BP) of \<140/90 mmHg or to no treatment for non-severe hypertension \< 160/110 mmHg (usual care). The primary endpoint is an adverse pregnancy composite comprised of preeclampsia with end-organ damage, medically indicated preterm delivery \<37 weeks 0 days gestation, fetal/neonatal/infant death, or placental abruption.
Conditions
- Hypertension in Pregnancy
- Obstetrical Complications
Interventions
Anti-hypertensive medication titrated to a BP goal of <140/90 mmHgDrug
Antihypertensive medication titrated to a BP goal of \< 140/90 mmHg initiated on labetalol or nifedipine ER following standard dosing guidelines. For first line treatment with labetalol, 200 mg twice daily will be initiated and escalated to a BP goal of \<140/90 mmHg to a maximum dose of 2,400 mg/day (1,200 mg twice daily or 800 mg three times daily). If a maximum daily dose of 2,400 mg or maximal tolerated dose of labetalol is reached without achieving goal BP \<140/90 mmHg, or at provider discretion, nifedipine ER can be added as a second agent and titrated as per the nifedipine ER algorithm outlined below. For first line treatment with nifedipine ER, dosing will be initiated at 30 mg daily and escalated to a goal BP \<140/90 mmHg to a maximum dose of 120 mg/day (120 mg daily or 60 mg twice daily). If the maximum daily dose or maximal tolerated dose of nifedipine ER is reached without achieving goal BP \<140/90, or at provider discretion, labetalol can be added as described above.
Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHgOther
Usual care will not receive anti-hypertensive medication upon randomization. Participants will only be prescribed antihypertensive medication if their BP increases to ≥160/110 mmHg and titrated to a BP goal of \<160/110 mmHg. They will receive IV and/or oral anti-hypertensive medication as per local institutional protocols for management of severe range BP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with the adverse pregnancy compositeTime frame: Randomization to 6 weeks postpartum / 6 weeks of life (a period of up to 23 weeks)
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama - Birmingham
Birmingham, Alabama
Regents of the University of California San Francisco
San Francisco, California
Northwestern University
Chicago, Illinois
Columbia University
New York, New York
University of North Carolina - Chapel Hill
Chapel Hill, North Carolina
Duke University
Durham, North Carolina
Case Western Reserve University
Cleveland, Ohio
Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Magee Women's Hospital
Pittsburgh, Pennsylvania
Brown Univeristy
Providence, Rhode Island
Baylor College of Medicine
Houston, Texas
University of Texas - Houston
Houston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.